Pacer Advisors
QNCX icon

Pacer Advisors’s Quince Therapeutics QNCX Stock Holding History

Pacer Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6
Closed -$45K – 1524
2021
Q1 		$45K Hold
6
– – ﹤0.01% 1450
2020
Q4 		$31K Buy
+6
New +$53.2K ﹤0.01% 1459

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Pacer Advisors's QNCX Position: Q2 2021 in Review

Pacer Advisors sold out of Quince Therapeutics (QNCX) in Q2 2021, closing a stake of 6 shares — an estimated $45K sold.

Pacer Advisors first reported a position in QNCX in Q4 2020 and held it in 2 quarters. The position peaked at $45K in Q1 2021. 100 funds tracked by Wall St. Rank hold QNCX as of Q2 2021.

  • Pacer Advisors reported no remaining Quince Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 6 Quince Therapeutics shares in Q2 2021, an estimated $45K.
  • Pacer Advisors first reported a position in Quince Therapeutics in Q4 2020 and held it in 2 quarters.
  • Pacer Advisors's Quince Therapeutics position peaked at $45K in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.